【摘要】 目的 探讨Ⅱb～Ⅲ期宫颈癌同期放化疗后口服尿嘧啶替加氟维持化疗的疗效及不良反应。方法 85例Ⅱb～Ⅲ期宫颈癌患者， 随机分为两组， 其中维持化疗组40例， 该组患者同期放化疗完成后给予口服尿嘧啶替加氟维持化疗至少1年， 对照组45例仅随访观察。比较两组患者近期疗效及不良反应。结果 维持化疗组无进展生存时间较对照组延长， 中位无进展生存时间分别为32个月与27个月， 差异有统计学意义(P=0.022<0.05)。两组骨髓抑制及胃肠道反应发生率比较， 差异无统计学意义(P>0.05)。结论 口服尿嘧啶替加氟维持化疗可改善Ⅱb～Ⅲ期宫颈癌生存质量， 且未明显增加毒性反应， 有望在临床上推广使用。

    【关键词】 尿嘧啶替加氟；宫颈癌；维持化疗

    【Abstract】 Objective To investigate the curative effect by oral administration of uracil-tegafur for maintenance chemotherapy of stageⅡb～Ⅲ cervical cancer after concurrent chemoradiotherapy. Methods A total of 85 patients with stageⅡb～Ⅲ cervical cancer were randomly divided into two groups. Maintenance chemotherapy group with 40 cases received oral administration of uracil-tegafur for at least 1 year after concurrent chemoradiotherapy. Control group with 45 cases received follow-up alone. Short-term effects and adverse reactions of the two groups were compared. Results The maintenance chemotherapy group had longer progression free survival than the control group ......